page logo
page logo

page

prolynxinc.com
prolynxinc.com • HQ: San Francisco, United States • Venture - Series Unknown 2020 • Founded 2019
HQ: San Francisco, United States • Venture - Series Unknown 2020 • Founded 2019
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Overview

Advancing Ultra-Long-Acting Medicines for Obesity and Related Metabolic Conditions. Prolynx is developing a next-generation portfolio of extended-duration therapeutics designed for once-monthly and once-quarterly dosing.

People

Daniel Santi
Executive Officer, Director
SEC Form D
Scott Karchmer
Executive Officer
SEC Form D
Anurag Bagaria
Director
SEC Form D
Marc Edwards
Director
SEC Form D
Michael Rabson
Director
SEC Form D
William Rutter
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Francisco United States
HQ

Financials

Total raised
$451k
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2020 $55k Details
Grant 2020 $246k Details
Grant 2017 $150k Details